Turkey Adalimumab Biosimilar Market Size & Outlook, 2026-2034

Turkey Adalimumab Biosimilar Market Insights

Based on Deep Market Insights findings, the Turkey Adalimumab Biosimilar Market reached USD 12.8 Million in 2025 and is estimated to attain USD 22.43 Million by 2034.
From 2026 to 2034, the Turkey market is expected to grow at a steady CAGR of 6.4%.
Within the By Type category, Adalimumab biosimilars dominated in 2025 in terms of market size contribution.
Over the forecast period, High-concentration formulations is forecasted to deliver the fastest growth, positioning it as the most lucrative By Type segment.

In 2025, Turkey represented 0.45% of the overall global Adalimumab Biosimilar Market size.
United States is projected to lead the global Adalimumab Biosimilar Market size by 2034.
Across Middle East and Africa, United Arab Emirates is anticipated to hold the dominant position in market size by 2034.
Saudi Arabia is forecasted to expand at the fastest pace in Middle East and Africa, attaining USD 75.36 Million by 2034.

Report Scope	Details
Base Year for Study	2025
Study Period	2022-2034
Historical Period	2022-2024
Forecast Period	2026-2034
Market Size In 2025	USD 12.8 Million
Market Size In 2034	USD 22.43 Million
Largest segment	Adalimumab biosimilars
Units	Revenue in USD Million
CAGR	6.4% (2026-2034)
Segmnetation Covered
By Type	Adalimumab biosimilars Interchangeable biosimilars High-concentration formulations Low-concentration formulations
By Indication	Rheumatoid arthritis Psoriasis Crohn’s disease Ulcerative colitis
By Route of Administration	Subcutaneous Prefilled syringes Auto-injectors Hospital administration
By End User	Hospitals Clinics Homecare Specialty pharmacies
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

By Type	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Adalimumab biosimilars	XX.x	XX.x	XX.x	6.08	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Interchangeable biosimilars	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
High-concentration formulations	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Low-concentration formulations	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

By Indication	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Rheumatoid arthritis	XX.x	XX.x	XX.x	5.17	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Psoriasis	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Crohn’s disease	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Ulcerative colitis	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

By Route of Administration	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Subcutaneous	XX.x	XX.x	XX.x	6.17	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Prefilled syringes	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Auto-injectors	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Hospital administration	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

By End User	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Hospitals	XX.x	XX.x	XX.x	5.24	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Clinics	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Homecare	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Specialty pharmacies	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x